Compare Merck & Co., Inc. (MRK) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance

Merck & Co., Inc.Trade

UBS Group AG Registered Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs UBS Group AG Registered Ordinary Shares — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while UBS Group AG Registered Ordinary Shares trades at $47.44 (market cap $144.63B). The key difference: Merck & Co., Inc. is far larger — about 2.4× UBS Group AG Registered Ordinary Shares's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.

	MRK	UBS
Market Cap	$352.29B	$144.63B
Volume	6,348,796	1,746,723
Sector	Health	Financials
52-Week High	$156.43	$55.72
52-Week Low	$82.49	$36.41
Typical Hold Time	98 Days	0 Days
Enterprise Value	$399.05B	$311.50B
Dividend Yield	2.38%	2.32%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.

The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.

UBS Group AG Registered Ordinary Shares

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRK

18% Buy82% Sell

Avg holding period · 98 Days

UBS

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

MRK

Global DPP-4 inhibitors market to grow to $15.5B by 2032, driven by type 2 diabetes demand and generics expansion.PRNewsWire · 17 hours agoNeutral HP, Merck, and Seagate paid dividends on Oct 7, with Merck leading in per-share payout and HP offering the highest yield.24/7 Wall Street · 23 hours agoBullish Dutch court blocks Merck's Keytruda SC sales in Europe for patent infringement.PRNewsWire · 1 day agoNeutral View details →

UBS

View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About UBS Group AG Registered Ordinary Shares

UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.